This week on "The Readout LOUD" podcast, a mother whose son has Duchenne muscular dystrophy shares her perspective on Sarepta ...

To suggest Sarepta Therapeutics may not survive its gene therapy crisis is a sobering claim to make, STAT's Adam Feuerstein ...

Sarepta Therapeutics faces an "arduous path” to try to get its gene therapy for Duchenne muscular dystrophy back onto the ...

The FDA on Tuesday rejected a skin therapy from Replimune Group, suggesting a hardened stance on drug approvals under new ...

Sarepta will halt all shipments of Elevidys, its drug for Duchenne muscular dystrophy patients, by Tuesday evening.

The FDA will request Sarepta Therapeutics stop all shipments of Elevidys, its gene therapy for Duchenne muscular dystrophy, ...

Sarepta Therapeutics announced it has laid off more than one-third of its workforce, a drastic cost-cutting move following ...

The FDA rejected a Duchenne muscular dystrophy cell therapy from Capricor Therapeutics, as a larger study of the treatment ...

Merck said it will buy Verona Pharma for $10 billion to bolster its lung-disease business and help replace the expected loss ...

Feuerstein, 48, grew up on Long Island, N.Y., and majored in political science at Emory University. He got his start in professional journalism while still in college, doing a six-month internship ...

Adam Feuerstein: Powers claims the company's cancer immunotherapy DCVax [ sic, DCVax-L] demonstrated a large and statistically significant survival benefit in a couple of phase I brain tumor ...

Adam Feuerstein's video message of why Antigenics (NASDAQ:AGEN) stinks is another fine example of why the small investor should not trust the big boys to ...